Cyclo Total Current Liabilities vs Accounts Payable Analysis

CYTH Stock

USD 0.73 0.03 4.29%

Cyclo Therapeutics financial indicator trend analysis is way more than just evaluating Cyclo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclo Therapeutics is a good investment. Please check the relationship between Cyclo Therapeutics Total Current Liabilities and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Total Current Liabilities vs Accounts Payable

Total Current Liabilities vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclo Therapeutics Total Current Liabilities account and Accounts Payable. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Cyclo Therapeutics' Total Current Liabilities and Accounts Payable is 0.94. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Cyclo Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclo Therapeutics' Total Current Liabilities and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Cyclo Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Current Liabilities i.e., Cyclo Therapeutics' Total Current Liabilities and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Cyclo Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cyclo Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Cyclo Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cyclo Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Cyclo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Issuance Of Capital Stock is increasing as compared to previous years. The Cyclo Therapeutics' current Sales General And Administrative To Revenue is estimated to increase to 5.52, while Selling General Administrative is projected to decrease to under 2.9 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	15.7M	16.8M	17.6M	18.5M
Cost Of Revenue	156.1K	138.9K	3.5M	3.7M

Total Operating Expenses Cost Of Revenue

Cyclo Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Other Current Liab	Short Term Investments	Current Deferred Revenue
Total Assets		0.15	0.74	0.85	-0.22	-0.96	-0.71	0.81	0.98	-0.28	-0.35	0.98	0.68	0.64	-0.23	-0.16	0.53	0.79	0.73	0.99	0.4	-0.28	-0.42	0.49	-0.3	-0.52
Short Long Term Debt Total	0.15		0.41	-0.15	0.61	0.11	-0.39	0.14	-0.03	0.57	0.31	-0.03	-0.32	0.58	0.41	-0.14	0.45	0.37	0.47	0.04	0.76	-0.21	-0.37	-0.54	-0.23	0.3
Total Current Liabilities	0.74	0.41		0.29	-0.27	-0.64	-0.95	0.94	0.68	-0.34	-0.48	0.68	0.25	0.94	-0.07	-0.2	0.74	0.95	0.99	0.75	0.79	-0.23	-0.18	0.33	-0.27	-0.6
Total Stockholder Equity	0.85	-0.15	0.29		-0.15	-0.89	-0.3	0.45	0.88	-0.19	-0.19	0.88	0.79	0.18	-0.26	-0.04	0.2	0.4	0.28	0.84	-0.04	-0.23	-0.43	0.5	-0.23	-0.33
Property Plant And Equipment Net	-0.22	0.61	-0.27	-0.15		0.42	0.39	-0.49	-0.35	0.99	0.73	-0.35	-0.35	-0.17	0.03	0.12	-0.35	-0.38	-0.22	-0.36	0.05	-0.12	-0.09	-0.68	-0.12	0.85
Net Debt	-0.96	0.11	-0.64	-0.89	0.42		0.63	-0.79	-0.99	0.47	0.46	-0.99	-0.74	-0.5	0.28	0.16	-0.45	-0.71	-0.62	-0.98	-0.22	0.2	0.37	-0.65	0.22	0.63
Retained Earnings	-0.71	-0.39	-0.95	-0.3	0.39	0.63		-0.91	-0.66	0.46	0.56	-0.66	-0.3	-0.95	-0.17	0.23	-0.9	-0.99	-0.94	-0.74	-0.82	0.24	0.29	-0.35	0.28	0.7
Accounts Payable	0.81	0.14	0.94	0.45	-0.49	-0.79	-0.91		0.8	-0.55	-0.6	0.8	0.44	0.81	-0.13	-0.26	0.7	0.93	0.93	0.85	0.58	-0.24	-0.13	0.59	-0.27	-0.76
Cash	0.98	-0.03	0.68	0.88	-0.35	-0.99	-0.66	0.8		-0.4	-0.42	1.0	0.71	0.55	-0.29	-0.17	0.46	0.74	0.67	0.99	0.28	-0.22	-0.39	0.6	-0.23	-0.58
Non Current Assets Total	-0.28	0.57	-0.34	-0.19	0.99	0.47	0.46	-0.55	-0.4		0.8	-0.4	-0.36	-0.24	0.03	0.12	-0.41	-0.45	-0.28	-0.42	-0.03	-0.15	-0.04	-0.68	-0.14	0.86
Non Currrent Assets Other	-0.35	0.31	-0.48	-0.19	0.73	0.46	0.56	-0.6	-0.42	0.8		-0.42	-0.25	-0.4	-0.01	0.02	-0.49	-0.55	-0.42	-0.46	-0.28	-0.19	0.03	-0.56	-0.17	0.7
Cash And Short Term Investments	0.98	-0.03	0.68	0.88	-0.35	-0.99	-0.66	0.8	1.0	-0.4	-0.42		0.71	0.55	-0.29	-0.17	0.46	0.74	0.67	0.99	0.28	-0.22	-0.39	0.6	-0.23	-0.58
Net Receivables	0.68	-0.32	0.25	0.79	-0.35	-0.74	-0.3	0.44	0.71	-0.36	-0.25	0.71		0.18	-0.25	-0.07	0.22	0.37	0.23	0.7	-0.14	-0.25	-0.07	0.57	-0.25	-0.46
Common Stock Shares Outstanding	0.64	0.58	0.94	0.18	-0.17	-0.5	-0.95	0.81	0.55	-0.24	-0.4	0.55	0.18		0.1	-0.21	0.81	0.94	0.95	0.64	0.9	-0.18	-0.3	0.1	-0.22	-0.49
Non Current Liabilities Total	-0.23	0.41	-0.07	-0.26	0.03	0.28	-0.17	-0.13	-0.29	0.03	-0.01	-0.29	-0.25	0.1		-0.19	0.56	0.11	-0.06	-0.22	0.34	-0.06	-0.35	-0.23	-0.05	0.0
Inventory	-0.16	-0.14	-0.2	-0.04	0.12	0.16	0.23	-0.26	-0.17	0.12	0.02	-0.17	-0.07	-0.21	-0.19		-0.26	-0.22	-0.27	-0.17	-0.02	-0.43	0.49	-0.08	-0.42	-0.02
Other Current Assets	0.53	0.45	0.74	0.2	-0.35	-0.45	-0.9	0.7	0.46	-0.41	-0.49	0.46	0.22	0.81	0.56	-0.26		0.87	0.73	0.56	0.8	-0.18	-0.41	0.2	-0.2	-0.6
Other Stockholder Equity	0.79	0.37	0.95	0.4	-0.38	-0.71	-0.99	0.93	0.74	-0.45	-0.55	0.74	0.37	0.94	0.11	-0.22	0.87		0.94	0.81	0.79	-0.25	-0.33	0.37	-0.28	-0.7
Total Liab	0.73	0.47	0.99	0.28	-0.22	-0.62	-0.94	0.93	0.67	-0.28	-0.42	0.67	0.23	0.95	-0.06	-0.27	0.73	0.94		0.73	0.79	-0.23	-0.21	0.29	-0.28	-0.55
Total Current Assets	0.99	0.04	0.75	0.84	-0.36	-0.98	-0.74	0.85	0.99	-0.42	-0.46	0.99	0.7	0.64	-0.22	-0.17	0.56	0.81	0.73		0.38	-0.24	-0.39	0.58	-0.26	-0.63
Short Term Debt	0.4	0.76	0.79	-0.04	0.05	-0.22	-0.82	0.58	0.28	-0.03	-0.28	0.28	-0.14	0.9	0.34	-0.02	0.8	0.79	0.79	0.38		-0.18	-0.29	-0.16	-0.22	-0.28
Intangible Assets	-0.28	-0.21	-0.23	-0.23	-0.12	0.2	0.24	-0.24	-0.22	-0.15	-0.19	-0.22	-0.25	-0.18	-0.06	-0.43	-0.18	-0.25	-0.23	-0.24	-0.18		-0.33	-0.24	0.99	0.34
Common Stock	-0.42	-0.37	-0.18	-0.43	-0.09	0.37	0.29	-0.13	-0.39	-0.04	0.03	-0.39	-0.07	-0.3	-0.35	0.49	-0.41	-0.33	-0.21	-0.39	-0.29	-0.33		0.17	-0.31	-0.08
Other Current Liab	0.49	-0.54	0.33	0.5	-0.68	-0.65	-0.35	0.59	0.6	-0.68	-0.56	0.6	0.57	0.1	-0.23	-0.08	0.2	0.37	0.29	0.58	-0.16	-0.24	0.17		-0.24	-0.73
Short Term Investments	-0.3	-0.23	-0.27	-0.23	-0.12	0.22	0.28	-0.27	-0.23	-0.14	-0.17	-0.23	-0.25	-0.22	-0.05	-0.42	-0.2	-0.28	-0.28	-0.26	-0.22	0.99	-0.31	-0.24		0.35
Current Deferred Revenue	-0.52	0.3	-0.6	-0.33	0.85	0.63	0.7	-0.76	-0.58	0.86	0.7	-0.58	-0.46	-0.49	0.0	-0.02	-0.6	-0.7	-0.55	-0.63	-0.28	0.34	-0.08	-0.73	0.35

Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

Cyclo Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.1M	14.2M	19.5M	4.2M	13.2M	13.9M
Total Current Liabilities	3.1M	3.7M	3.8M	3.5M	8.5M	8.9M
Total Stockholder Equity	936.0K	10.5M	15.7M	734.5K	4.8M	2.6M
Property Plant And Equipment Net	64.6K	87.9K	77.2K	56.7K	929.3K	505.7K
Net Debt	(2.7M)	(12.7M)	(16.4M)	(1.5M)	(8.2M)	(7.8M)
Retained Earnings	(25.1M)	(34.1M)	(48.3M)	(63.8M)	(83.9M)	(79.7M)
Accounts Payable	3.1M	3.5M	3.7M	2.2M	4.9M	5.1M
Cash	2.8M	12.8M	16.6M	1.5M	9.2M	9.7M
Non Current Assets Total	155.2K	137.7K	84.5K	56.7K	929.3K	694.6K
Non Currrent Assets Other	90.6K	49.8K	7.3K	(56.7K)	38.3K	36.4K
Cash And Short Term Investments	2.8M	12.8M	16.6M	1.5M	9.2M	9.7M
Net Receivables	182.5K	111.8K	539.1K	55.0K	122.4K	105.2K
Common Stock Shares Outstanding	1.1M	1.6M	6.4M	8.4M	16.3M	17.1M
Liabilities And Stockholders Equity	4.1M	14.2M	19.5M	4.2M	13.2M	13.9M
Non Current Liabilities Total	36.1K	62.9K	18.0K	3.5M	22.5K	21.4K
Inventory	242.6K	237.9K	227.4K	254.5K	254.4K	250.7K
Other Current Assets	749.2K	854.4K	2.1M	4.6M	2.7M	2.8M
Other Stockholder Equity	26.0M	44.5M	64.0M	64.5M	88.6M	93.0M
Total Liab	3.2M	3.7M	3.8M	3.5M	8.5M	8.9M
Total Current Assets	4.0M	14.1M	19.4M	4.2M	12.3M	12.9M
Common Stock	12.2K	477.0	841.0	849.0	2.9K	3.7K
Net Tangible Assets	936.0K	10.5M	15.7M	734.5K	844.7K	802.5K
Other Assets	129.7K	90.6K	49.8K	7.3K	6.6K	6.2K
Property Plant Equipment	64.6K	87.9K	77.2K	56.7K	65.2K	56.7K
Net Invested Capital	936.0K	10.6M	15.8M	734.5K	4.8M	5.5M
Property Plant And Equipment Gross	64.6K	87.9K	159.3K	158.2K	1.1M	1.1M
Net Working Capital	816.9K	10.4M	15.6M	677.9K	3.9M	5.2M
Capital Stock	12.2K	477.0	841.0	849.0	2.9K	3.5K

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:

How To Invest In Cyclo

Details

Is Cyclo Stock a good investment?

Details

What is Cyclo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.90)

Revenue Per Share

0.046

Quarterly Revenue Growth

0.051

Return On Assets

(2.82)

Return On Equity

(226.64)

The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclo Total Current Liabilities vs Accounts Payable Analysis

Total Current Liabilities vs Accounts Payable

Total Current Liabilities vs Accounts Payable Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Accounts Payable

Cyclo Therapeutics fundamental ratios Correlations

Cyclo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclo Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.96	Total Assets
Common Stock Shares Outstanding	- 0.95	Retained Earnings